Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor

ABSTRACT

An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated.

TECHNICAL FIELD

The present invention relates to an improving agent for dysfunction due to nerve damage and to an Rho kinase activation inhibitor.

BACKGROUND ART

In human central nervous system (CNS), it is very difficult to regenerate the neuronal axon which was once injured due to spinal cord injury, cerebrovascular disease, cerebral injury or the like and, once a deficit symptom of motor function or sensory function happens, recovery therefrom is difficult whereby one shall suffer from the aftereffects thereof throughout his/her life. That has been well known not only among persons skilled in the art but also among common people and, in recent years, the reasons thereof have been gradually clarified. For the recovery of neural function, there is needed the regeneration of neuronal network by an elongation of neuronal axon cut by injury beyond the injured area resulting in synapse formation connected to the secondary neuron. However, the environment surrounding the central nervous system is equipped with a regeneration inhibiting function via plurality of regeneration suppressing factors for neuronal axons for preventing the disordered formation of synapse and this function disturbs the regeneration of neuronal network. Chondroitin sulfate proteoglycan has been known as one of the regeneration suppressing factors for neuronal axon and has been reported to inhibit the axonal regeneration in the injured area (refer, for example, to Non-Patent Literature 1). Further, in Patent Literature 1, the fact that keratan sulfate plays an important role in the formation of glial scar inhibiting the axonal regeneration is clarified by an experiment in brain-injured model using mice where N-acetylglucosamine 6-O-sulfotransferase 1 (GlcNAc6ST-1) gene which is necessary for biosynthesis of keratan sulfate in the brain is knocked out. In the same document, it is proposed that substances which inhibit the synthesis and the physiological activity of keratan sulfate are effective for the prevention and the treatment of nerve damage from the experimental results that non-expression of keratan sulfate in the injured area results in the suppression of the formation of glial scar.

Further, expression of neuropathic pain is exemplified as a symptom which greatly lowers the QOL (quality of life) among sensory neuron dysfunction. Neuropathic pain is a pain caused by disorder of the central nerve or the peripheral nerve and examples thereof include spontaneous pain, hyperalgesic reaction where the threshold for invasive stimulation lowers and mechanical allodynia where non-invasive mechanical stimulation and tactile stimulation which usually do not induce the pain are erroneously recognized as sharp pain. Examples of the diseases expressing neuropathic pain include cerebral disorder, multiple sclerosis and spinal cord injury as central ones and diabetes mellitus and herpes zoster as peripheral ones. Among neuropathic pains, allodynia is characterized in that intractable and burning pain and piercing pain continue for a long period of time without intermittence and is also a cause of the reduction in the effect of rehabilitation due to the pain. There has been almost no satisfactory drug therapy for neuropathic pain and there has been a demand for the development of drugs which satisfy both pharmaceutical effect and safety. However, the development of the drug has been unable to make satisfactory progress. One of the reasons therefor is that it is thought that the mechanism of pathogenesis is not single but many of them are entangled in a complicated manner. Details of the onset mechanism for allodynia is still ambiguous even at this time but, in recent years, findings for ATP (adenosine triphosphate) which has been known as a pain-causing substance have started to be reported. It has been gradually aware of that ATP strongly activates spinal microglia and causes potentiation of production of various mediators assisting the abnormal neuronal network formation, synapse transportation and release of neurotransmitters with re-construction of cell skeleton whereby it participates in neuropathic pain, and ATP as such also activates Rac which is one of an Rho family (Non-Patent Literature 2).

It has been also being aware of that spinal microglia of dorsal horn is activated by nerve injury and that stimulation of P2X4 receptor which is strongly expressed therein causes neuropathic pain, and it has been proposed of the participation of Rho kinase signal transduction system as one of the routes of cascade of the activation as such (Non-Patent Literature 2).

Patent Literature 1: JP-A-2006-290842

Non-Patent Literature 1: Niederost, B. P., Zimmermann, D. R., Schwab, M. E. & Bandtlow, C. E. Bovine CNS myelin contains neurite growth-inhibitory activity associated with chondroitin sulfate proteoglycans. J. Neurosci. 19, 8979-8989 (1999).

Non-Patent Literature 2: Honda, S. et al., 2001. Extracellular ATP or ADP Induce Chemotaxis of Cultured Microglia through Gi/o-Coupled P2Y Receptors. J. Neurosci. 21(6), 1975-1982.

DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention

As above-mentioned, research and development for the prevention and the treatment of nerve damage have been eagerly carried out day to day but, unfortunately, no satisfactory results have been achieved yet at present. In fact, as above-mentioned, although there is a proposal in the Patent Literature 1 that substances which inhibit the synthesis and the physiological activity of keratan sulfate are effective for the prevention and the treatment of nerve damage, no result where specific substances are actually effective has been available yet.

Under such circumstances, an object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage.

Means for Solving the Problems

In view of the above, the present inventors have carried out intensive studies and, as a result, they have found that an endo-O—N-acetylglucosaminidase type enzyme which is one of the keratan sulfate degrading enzymes and hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone improves dysfunction due to nerve damage such as motor neuron dysfunction or sensory neuron dysfunction (such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction) and that such an action is mediated by the suppression of an Rho kinase activation by keratan sulfate.

The present inventors have now achieved an idea that, when an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone (hereinafter, it will be sometimes referred to as “an endo-β-N-acetylglucosaminidase type keratan sulfate degrading enzyme”) is continuously administered to the injured area of an individual immediately after nerve damage, the spinal cord injury happens for example, so as to remove a keratan sulfate backbone of keratan sulfate proteoglycan, that releases the continuous abnormal activation of nerve cells and non-nerve cells such as glia cell caused by proteoglycan and results in the release of an abnormal axonal guidance function by proteoglycan and also in the therapeutic effect for neuropathic pain. On the basis of the idea as such, the present inventors have for the first time found that, when an endo-β-N-acetylglucosaminidase type keratan sulfate degrading enzyme is continuously administered to the injured area in the intrathecal cavity of model rats for spinal cord injury, improvement of motor neuron function and sensory neuron function is promoted and that, particularly due to the improvement of the latter, neuropathic pain, particularly allodynia, is able to be improved.

An improving agent for dysfunction due to nerve damage of the present invention achieved by the above-mentioned finding (hereinafter, it will be sometimes referred to as an improving agent of the present invention) is characterized in that, as mentioned in claim 1, it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient.

The improving agent mentioned in claim 2 is characterized in that, in the improving agent mentioned in claim 1, the nerve damage is that arising from spinal cord injury.

The improving agent mentioned in claim 3 is characterized in that, in the improving agent mentioned in claim 1, the nerve damage is amyotrophic lateral sclerosis.

The improving agent mentioned in claim 4 is characterized in that, in the improving agent mentioned in any of claims 1 to 3, the dysfunction due to nerve damage is motor neuron dysfunction.

The improving agent mentioned in claim 5 is characterized in that, in the improving agent mentioned in any of claims 1 to 3, the dysfunction due to nerve damage is sensory neuron dysfunction.

The improving agent mentioned in claim 6 is characterized in that, in the improving agent mentioned in claim 5, the sensory neuron dysfunction is neuropathic pain.

The improving agent mentioned in claim 7 is characterized in that, in the improving agent mentioned in claim 6, the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction.

As mentioned in claim 8, an improving agent for neuropathic pain of the present invention is also characterized in that, it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient.

As mentioned in claim 9, an Rho kinase activation inhibitor of the present invention (hereinafter, it will be sometimes referred to as an inhibitor of the present invention) is characterized in that, it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient.

Further, as mentioned in claim 10, an agent for treating nerve damage of the present invention comprising an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient for a continuous administration to a neuropathic site at the dose of 0.3 milliunit (mU) to 15000 mU per day to an adult human.

EFFECT OF THE INVENTION

In accordance with the present invention, an endo-β-N-acetylglucosaminidase type keratan sulfate degrading enzyme is provided as an active ingredient for an improving agent for dysfunction of motor neuron and of sensory neuron due to nerve damage such as spinal cord injury or, to be more specific, for an improving agent for neuropathic pain for example. There is also provided an agent for administering to nerve damage for a continuous administration to a neuropathic site, which comprises a specific amount of an endo-β-N-acetylglucosaminidase type keratan sulfate degrading enzyme.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 Experimental Result of Example 1, No. 1: This is a graph showing the dose response of the therapeutic effect in an evaluation of the recovery of hind paw motor function (BBB Test) of Bc keratanase II.

FIG. 2 (the same as above): This is a graph showing the dose response of the therapeutic effect of Ks36 keratanase II.

FIG. 3 (the same as above): This is a graph showing the comparison in the therapeutic effects by Bc keratanase II and Ks36 keratanase II when the administered concentration is 0.05 U/200 μl.

FIG. 4 (the same as above): This is a graph showing the comparison in the therapeutic effects by Bc keratanase II and Ks36 keratanase II when the administered concentration is 0.000025 U/200 μl.

FIG. 5 (the same as above): This is a graph showing the comparison in the therapeutic effects by Bc keratanase II, inactivated Bc keratanase II and Ps keratanase when the administered concentration is 0.05 U/200 μl.

FIG. 6 Experimental Result of Example 1, No. 2: This is a graph showing the comparison in the therapeutic effects by Bc keratanase II and Ks36 keratanase II when the administered concentration is 0.05 U/200 μL in an evaluation of the recovery of hind paw motor function (Grid Test).

FIG. 7 (the same as above): This is a graph showing the comparison in the therapeutic effects by Bc keratanase II and Ks36 keratanase II when the administered concentration is 0.000025 U/200 μL.

FIG. 8 Experimental Result of Example 1, No. 3: This is a graph showing the comparison in the therapeutic effects by Bc keratanase II and Ks36 keratanase II when the administered concentration is 0.05 U/200 μL in an evaluation of the recovery of hind paw motor function (Foot Print Test).

FIG. 9 Experimental Result of Example 1, No. 4: This is a graph showing the comparison in the therapeutic/improving effects by Bc keratanase II and Ks36 keratanase II when the administered concentration is 0.05 U/200 μL in an evaluation of a therapeutic/improving effect for thermal allodynia (Tail Flick Test).

FIG. 10 Experimental Result of Example 1, No. 5: This is a graph showing the comparison in the therapeutic/improving effects by Bc keratanase II and Ks36 keratanase II when the administered concentration is 0.05 U/200 μL in an evaluation of the therapeutic/improving effect for mechanical allodynia (Touch Test).

FIG. 11 Experiment of Example 2, No. 1: This is a graph showing a releasing effect of Ks36 keratanase II to a neurite outgrowth-inhibiting action by keratan sulfate.

FIG. 12 Experiment of Example 2, No. 2: These are pictures under a fluorescence microscope showing a releasing effect of Y27632 (Rho kinase inhibitor, Sigma) to a neurite outgrowth-inhibiting action by keratan sulfate.

FIG. 13 (the same as above): This is a graph showing an Rho kinase activation suppressing action of Ks36 keratanase II.

FIG. 14 This is a result of western blotting showing the expression of keratan sulfate in spinal cord of ALS model mice in Example 3.

FIG. 15 (the same as above): These are pictures under a fluorescence microscope showing the expression of keratan sulfate in microglia.

BEST MODE FOR CARRYING OUT THE INVENTION

An improving agent of the present invention is characterized in that the agent comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone (an endo-β-N-acetylglucosaminidase type keratan sulfate degrading enzyme) as an active ingredient. The endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone is a keratan sulfate degrading enzyme, also known as keratanase II, and the enzyme per se is a known substance (hereinafter, the endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone will be abbreviated as keratanase II). Keratanase II is an enzyme derived from microbes and has been known to be produced by Ks36 strain of bacteria belonging to genus Bacillus (Accession Number for the microbe: FERM P-10204) (refer, if necessary, to Japanese Patent No. 2726274; hereinafter, keratanase II produced by Ks36 strain will be abbreviated as Ks36 keratanase II). A heat resistant keratanase II having an excellent stability against heat where the optimum reaction temperature is 50 to 60° C. has been known as well and the enzyme has been known to be produced by Bacillus circulans KsT202 strain (Accession Number for the microbe: FERM BP-5285) (hereinafter, the heat resistant keratanase II will be abbreviated as Bc keratanase II). Bc keratanase II is characterized in that it degrades keratan sulfate whereupon sulfated keratan sulfate disaccharide and keratan sulfate tetrasaccharide are mainly produced (refer, if necessary, to Japanese Patent No. 3734504, U.S. Pat. No. 5,840,546, European Patent No. 0798376 B1, etc.). Bc keratanase II may be a genetically recombinant type heat resistant keratanase II which is produced, for example, by transferring the heat resistant keratanase II gene cloned from Bacillus circulans KsT202 strain to a host such as Escherichia coli (refer, if necessary, to JP-A-2004-24189 and Gen Bank: Accession No. AY188989 http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore& id=32454884; hereinafter, genetically recombinant type heat resistant keratanase II will be abbreviated as rBC keratanase II). The total amino acid sequence of rBC keratanase II described in the above-mentioned JP-A-2004-24189 is attached hereto as SEQ ID No. 1.

Although both Ks36 keratanase II and Bc keratanase II are the endo-β-N-acetylglucosaminidase type enzymes, they are different in terms of reactivity to high concentrated keratan polysulfate (keratan sulfate having a high degree of sulfation), optimum pH, pH stability, optimum temperature, temperature stability, influence of inhibition by drugs, etc. and, therefore, they are essentially different enzymes (refer, if necessary, to Japanese Patent No. 3734504, U.S. Pat. No. 5,840,546, European Patent No. 0798376 B1, etc.). As to the enzyme for an active ingredient of an improving agent for dysfunction due to nerve damage of the present invention, those two kinds of enzymes are advantageously listed wherein Bc keratanase II is preferred and rBC keratanse II is more preferred.

Incidentally, keratanase II used in the present invention is not limited to the above-mentioned exemplified enzymes so far as it is an endo-O—N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone and, further, there is no limitation for the origin and the enzymatic properties thereof.

Keratanase II improves motor neuron dysfunction and sensory neuron dysfunction caused by various nerve damages such as nerve damage arising from spinal cord injury or amyotrophic lateral sclerosis, and the action as such is mediated by the suppression of an Rho kinase activation by keratan sulfate. Rho kinase (ROCK) is a small GTPase (guanosine triphosphate phosphatase) existing in cytoplasm and having an activity of hydrolyzing GTP (guanosine triphosphate) and is an important enzyme for phosphorylation which conducts various controls for cell shape and locomotion by controlling an actin cytoskeletal system or tubulin. This enzyme was found in 1990s and is activated by several intracellular factors such as Rho. When an Rho kinase signal transduction system is activated, an actin cytoskeletal system is inactivated and, as a result, an axonal regeneration is inhibited and decay of growth cone is induced. The facts that the inhibition of the axonal regeneration induced by keratan sulfate is associated with an Rho kinase activation and that an improving action of keratanase II for dysfunction due to nerve damage is mediated by the suppression of the Rho kinase activation have been firstly found by the present inventors and, on the basis of such findings, the present invention provides a novel improving agent for dysfunction due to nerve damage wherein the control of the Rho kinase signal transduction system is a concept.

Keratanase II such as Ks36 keratanase II or Bc keratanase II which is an active ingredient for an improving agent of the present invention or an inhibitor of the present invention (hereinafter, both agents will be sometimes referred to as the drug of the present invention) is made into a parenteral preparation by a common method same as in the case of common parenteral enzyme preparations, parenterally administered to mammals (such as humans, non-human primates, rats, mice, rabbits, cattles, horses, pigs, dogs or cats) by an administration route corresponding to object disease and used for the treatment or the prevention of the aimed disease of the animal.

Examples of the parenteral preparation include liquid preparation (such as solution preparation, suspension preparation, eye drop, nose drop or locally infusion agent to brain, intrathecal cavity, skin, etc.), solid preparation (such as freeze-dried preparation, powder preparation, granule preparation, microcapsule, liposome or liposphere) and semisolid preparation (such as ointment). When the drug of the present invention is manufactured as liquid preparation for example, it is able to be manufactured by dissolving or dispersing keratanase II of a pharmaceutically acceptable grade into a solution to which water for injection, pharmaceutically acceptable additives or carriers such as isotonizing agent (e.g., sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, glucose or propylene glycol), buffer agent (e.g., phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, glutamate buffer or c-aminocaproate buffer), preservative (e.g., p-hydroxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid or borax), nonionic surfactant (e.g., polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester or polyoxyethylene polyoxypropylene glycol), thickener (e.g., polyvinyl alcohol), stabilizer/activity retainer (e.g., serum albumin, gelatin, sucrose, polyethylene glycol, dextran, lactose, maltose, mannitol, xylitol, sorbitol, inositol, sodium edetate, sodium citrate or ascorbic acid), pH adjusting agent (e.g., hydrochloric acid, sodium hydroxide, phosphoric acid or acetic acid), solubilizing aid, antioxidant or substance effective for prevention of adsorption with container are appropriately added. It is also possible that such liquid preparation is dried by a drying method (such as freeze-drying) which does not affect the pharmacological function of keratanase II such as activity whereupon solid preparation which is a type being dissolved before use is prepared. Specific example thereof is that keratanase II of a pharmaceutically acceptable grade is dissolved or suspended in physiological saline, water for injection, isotonic liquid, oily liquid or the like to prepare liquid preparation.

The drug of the present invention prepared as such is administered by an administering method depending upon object disease, degree of symptom, subject to be administered, etc. whereby dysfunction caused by nerve damage is able to be improved, treated or prevented. An example thereof is a method where it is locally administered to the site suffering from nerve damage or surroundings thereof and such a method is preferred. To be more specific, it is possible to conduct a continuous administration to subarachnoid cavity (intrathecal administration) by an osmotic pressure pump using a microtube and such a continuous administration is preferred when an object of the present invention is taken into consideration.

Dose and administering period of the drug of the present invention is to be appropriately determined by medical specialists such as a medical doctor taking the conditions such as object disease, animal species, age or body weight to be administered, degree of symptom or health condition of the subject into consideration and there is no particular limitation provided that the dose and the period are effective for suppressing an activation of Rho kinase in diseased site or for degrading a keratan sulfate backbone of keratan sulfate proteoglycan in glial scar.

Daily dose for intrathecal administration of an improving agent of the present invention to a rat (body weight: 0.3 kg; cerebrospinal fluid amount: 0.3 mL) of a spinal cord-injured model is about 1.5 microunit (μU) (0.000025 U/200 μL) to 30 milliunit (mU), preferably about 0.3 mU (0.005 U/200 μL) to 10 mU, and most preferably about 3.0 mU (0.05 U/200 μL) in terms of enzyme unit of keratanase II. “U/200 μL” in the parentheses means a concentration and an enzyme liquid preparation having each concentration is administered in a dose of 12 μL per day.

When this is converted to an adult human (body weight: 60 kg; cerebrospinal fluid amount: 150 mL) with a presumption that body weight and cerebrospinal fluid amount of a rat are 0.3 kg and 0.3 mL, respectively, it is about 200 times on the basis of body weight while, when it is converted on the basis of cerebrospinal fluid amount by taking the direct intrathecal administration into consideration, it is about 500 times. Accordingly, the dose to an adult human (body weight in average: 60 kg; cerebrospinal fluid amount in average: 150 mL) is as follows.

Thus, the daily dose for intrathecal administration in terms of a conversion based on body weight is about 0.3 mU to 6000 mU, preferably about 60 mU to 2000 mU, and most preferably about 600 mU.

Then the daily dose for intrathecal administration in terms of a conversion based on cerebrospinal fluid amount is about 0.75 mU to 15000 mU, preferably about 150 mU to 5000 mU, and most preferably about 1500 mU.

Accordingly, when the above-mentioned converting methods are considered as a whole, the daily dose for intrathecal administration is about 0.3 mU to 15000 mU, preferably about 60 mU to 5000 mU, and most preferably about 600 mU to 1500 mU.

The administering period is to be decided by medical specialists such as a medical doctor depending upon the symptoms taking expressed amount of keratan sulfate proteoglycan in the injured area and possibility of adverse event, etc. into consideration and a yardstick thereof in the case of a continuous administration is up to about eight weeks, preferably up to about four weeks, and more preferably up to about two weeks after the injury. Time for starting the administration is preferred to be immediately after the injury or three days to about one week after the injury.

Since the preferred specific activity of keratanase II which is an active ingredient is about 2 U/mg protein or higher, the above-mentioned daily dose for intrathecal administration is that about 0.3 mU, 15000 mU, 60 mU, 5000 mU, 600 mU and 1500 mU correspond to not more than about 0.15 microgram (μg), not more than about 7500 μg, not more than about 30 μg, not more than about 2500 μg, not more than about 300 μg and not more than about 750 μg, respectively in terms of the weight of enzyme protein. One unit (1 U) of enzyme amount is defined as enzyme amount producing reducing terminal corresponding to 1 μmol of galactose per minute when a reaction is conducted at 37° C. for 10 minutes using keratan polysulfate derived from cartilage of shark as a substrate (refer, if necessary, to JP-A-2004-24189).

The enzyme amount or the concentration per unit preparation of the drug of the present invention is set depending upon the above-mentioned dose and the preparation is not always necessary to make the enzyme amount or the concentration upon the administration but, for example, dilution may be conducted immediately before the administration or upon the administration to an effective and safe concentration by using diluent. Accordingly, the present invention also provides a kit in which such diluent is combined with the above-mentioned drug of the present invention.

Since the drug of the present invention is medicament with an object of administration to human body, etc., it is preferred that keratanase II which is an active ingredient is in a pharmaceutically acceptable grade and that impurities such as endotoxin, nucleic acid or protease derived from the microbes wherefrom the present enzyme is produced are to be removed as much as possible. Amounts of endotoxin, nucleic acid and protease are to be not more than the detecting limit by the conventional analytic method. For example, with regard to endotoxin, its amount is preferred to be not more than 5.0 pg/100 U when measured by Toxicolor (registered trade mark) System of Seikagaku Corporation. With regard to nucleic acid, it is preferred to be not more than the detecting limit when measured by Threshold Method (DNA measuring device: Threshold (manufactured by Molecular Devices)). With regard to protease, its amount is preferred to be not more than 0.1% to the total protein when measured by using FITC-casein as a substrate.

The improving agent of the present invention is used for improvement, treatment or prevention of dysfunction caused by acute disorder, subacute disorder or chronic disorder of central nerve system (CNS) including spinal cord and brain or peripheral nerve system. Examples of the object disease for the improving agent of the present invention include nerve injury, neural degenerative disorder or neural dysfunction including contusion of central nerve, traumatic brain injury, other brain injury, apoplexy, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), brachial plexus injury, ambliophia, spinal cord injury, Alzheimer's disease, Parkinsonism, although it is not limited thereto. Spinal cord injury includes disease such as crush of neuron and traumatic injury caused by traffic accident, accidental fall, contusion, gunshot wound and other injury. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction (such as motor function disorder of the four limbs and the trunk caused by dysfunction, disorder and paralysis of motor neuron) and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction (such as hypertarachia, dysesthesia, numbness of the four limbs, facial nerve paralysis, etc. caused by dysfunction, disorder and paralysis of sensory neuron) of the object to be treated (patient).

It is also possible that the drug of the present invention is used for the treatment together with other drug which has been known to have an improving effect for nerve damage such as spinal cord injury.

An example of such a drug is that which comprises chondroitinase having an action of degrading chondroitin sulfate proteoglycan as an active ingredient.

Chondroitinase is a lyase which degrades chondroitin sulfate into an unsaturated disaccharide in an eliminating manner. Examples of the enzyme which is available at present will be listed below.

-   -   Chondroitinase ABC (derived from Proteus vulgaris; sold by         Seikagaku Biobusiness Corporation).     -   Chondroitinase AC I (derived from Flavobacterium heparinum; sold         by Seikagaku Biobusiness Corporation).     -   Chondroitinase AC II (derived from Arthrobacter aurescens; sold         by Seikagaku Biobusiness Corporation).     -   Chondroitinase AC II (derived from Flavobacterium sp. Hp 102).     -   Chondroitinase B (derived from Flavobacterium heparinum; sold by         Seikagaku Biobusiness Corporation).     -   Chondroitinase C (derived from Flavobacterium sp. Hp 102)     -   Chondroitinase AC (recombinant, derived from Flavobacterium         heparinum; sold by IBEX Technologies Inc.)     -   Chondroitinase B (recombinant, derived from Flavobacterium         heparinum; sold by IBEX Technologies Inc.)

Chondroitinase ABC [EC 4.2.2.20 or EC 4.2.2.4] is an enzyme which cleaves an N-acetylhexosaminide bond of glycosaminoglycan containing chondroitin sulfate in an elimination reaction manner whereupon an unsaturated disaccharide having a Δ4-hexuronic acid residue in a non-reducing terminal is mainly produced. It is an enzyme strongly catalyzing the degradation of chondroitin sulfate A derived from cartilage of mammals (containing abundant chondroitin-4-sulfate), chondroitin sulfate C derived from cartilage of shark (containing abundant chondroitin-6-sulfate) and chondroitin sulfate B (dermatan sulfate) derived from skin of mammals while weakly catalyzing the degradation of hyaluronic acid, and it also degrades chondroitin sulfate A, dermatan sulfate and chondroitin sulfate C in a chondroitin sulfate side chain of chondroitin sulfate proteoglycan (Yamagata, T. et al., J. Biol. Chem., 243: 1523-1535 (1968); Hamai A. et al., J. Biol. Chem. 272: 9123-9130 (1997)). This enzyme is commercially available as a reagent for the research in, for example, removal of mucopolysaccharide from animal tissue or identification of mucopolysaccharide in the tissue, as an enzyme product produced by bacteria such as Proteus vulgaris from Seikagaku Biobusiness Corporation with a code number 100330 (Chondroitinase ABC (Proteus vulgaris)) and code number 100332 (Chondroitinase ABC Protease Free (Proteus vulgaris)). In addition, an enzyme which is purified in higher purity (being a single protein containing no endotoxin, nucleic acid, contaminating proteins, etc.) having very high specific activity is more preferred since it has been subjected to a clinical test as a treating agent for disc herniation and has been fully clarified for its action to living body. Particularly, the chondroitinase ABC having high purity and high specific activity described in Japanese Patent No. 3980657, U.S. Pat. No. 6,184,023, U.S. Pat. No. 5,773,277, and U.S. Pat. No. 5,763,205, etc. is most preferred. Incidentally, the above chondroitinase ABC is the same enzymes as the following enzymes having other names.

-   -   Chondroitinase ABC Type 1     -   Chondroitin ABC endolyase 1     -   Chondroitin ABC lyase I     -   Chondroitin sulfate endolyase     -   Chondroitin ABC eliminase

Gene of the above-mentioned substance having a chondroitinase ABC activity has been cloned and amino acid sequence of the protein and DNA base sequence coding therefor have been also identified (U.S. Pat. No. 5,578,480, JP-A-2007-520447 (WO 2004/103299)). As to the representative amino acid sequence, that which is described in U.S. Pat. No. 5,578,480 may be exemplified. This amino acid sequence comprises 1021 amino acid residues in which amino acids of 1 to 24 constitute a signal sequence and a mature protein comprises 997 amino acid residues (amino acids of 25 to 1021). As to another representative amino acid sequence, that which is described in the database for amino acid sequences (UniProtKB/Swiss-Prot: Entry name CABCPROVU, Primary accession number P59807, Protein name Chondroitin ABC endolyase 1 [Precursor]) may be exemplified. Although this amino acid sequence also comprises 1021 amino acid residues, it is different in two amino acids from the amino acid sequence described in U.S. Pat. No. 5,578,480 (No. 694: Q→E, No. 738: D→N). In addition, although amino acid sequence described in SEQ ID NO: 1 of US 2006/0233782 A1 is of a mature protein whereby it comprises 997 amino acid residues, it is different in four amino acids from amino acids of 25 to 1021 in the amino acid sequence described in U.S. Pat. No. 5,578,480 (No. 154: A→T, No. 295: I→T, No. 694: Q→E, No. 738: D→N). Thus, even when an enzyme is that where at least four amino acids (such as Nos. 154, 295, 694 and 738) are substituted with other amino acids based on the amino acid sequence described in U.S. Pat. No. 5,578,480, that is still able to be regarded as an enzyme having the identical chondroitinase ABC activity.

It is also possible that the drug where the improving agent of the present invention is made into a pharmaceutical preparation is used for the treatment together with other drug which has been known to have an improving effect for neuropathic pain. Examples of the other drug as such include NSAIDs, opioid and adjuvant analgesics as exemplified below. Thus, examples of opioid analgesic include morphine, fentanyl, oxycodone, codeine phosphate, pethidine, buprenorphine, tramadol, pentazocine and butorphanol. Examples of adjuvant analgesics include a tricyclic type (such as amitriptyline or nortriptyline), a tetracyclic type (such as Tetramide), SSRI (such as paroxetine or fluvoxamine and SNRI (milnacipran) which are antidepressants; examples of anticonvulsant include carbamazepine, lamotrigine, zonisamide, valproic acid and clonazepam; examples of antispasmodic include baclofen; examples of antiarrhythmic include lidocaine and mexiletine; examples of NMDA receptor antagonist include ketamine, dextromethorphan, amantadine and ifenprodil; and examples of a preparation containing an extract from the inflamed skin of rabbit inoculated with vaccinia virus include Neurotropin. Calcium channel blocker (bonding to α2δ subunit) which has been receiving public attention recently such as gabapentin (anticonvulsant) and pregabalin may be also listed. It is also possible to use together with a drug having an antiinflammatory action such as steroidal agent (e.g., methylprednisolone sodium succinate, dexamethasone and betamethasone) or fasudil which is an Rho kinase inhibitor.

EXAMPLES

The present invention will now be more specifically illustrated by way of the following Examples, although the present invention should not be interpreted by limiting to the following description.

Example 1 Improving Action of Keratanase II for Dysfunction after Spinal Cord Injury (Experimental Method)

S. D. Rats (Nippon SLC; female; 9 weeks age) were used in this study. The animals were anesthetized with ether and ketamine cocktail, the ninth and the twelfth thoracic vertebrae were laminectomized and induced spinal cord injury on the ninth thoracic vertebra by means of contusion where 1H-0400 Impactor was used. After the injury, small incision was done to dura mater of the twelfth thoracic vertebra and a microtube was inserted into the subarachnoid cavity under a surgical microscope. An osmotic pressure pump (Alzet Osmotic Pump) in which a test sample was previously filled was connected to the microtube. The tube and the pump were sutured to the interspinal ligament and the muscle. Afterward, the muscles and skin were closed in layers. After the operation, all animals were orally given antibiotics for two weeks. The bladder was compressed by manual abdominal pressure once a daily until bladder function restored. The test sample was continuously administered intrathecally for 14 days since the stage of immediately after the injury (administering rate: 12 μl/24 hours; total dose: 168 μL/14 days). The test sample was the following five types.

(1) Bc keratanase II (a heat resistant keratanase II produced by the bacteria of the species Bacillus circulans KsT202 strain described in Japanese Patent No. 3734504) (0.000005 U/200 μL, 0.000025 U/200 μL and 0.05 U/200 μL)

(2) Ks36 keratanase II (keratanase II produced by Ks36 strain of bacteria belonging to genus Bacillus described in Japanese Patent No. 2726274) (0.000025 U/200 μL, 0.0005 U/200 μL, and 0.05 U/200 μL)

(3) Inactivated Bc keratanase II (an enzyme prepared by inactivation of the enzymatic activity of Bc keratanase II (0.05 U/200 μL) at 100° C. (for 10 minutes))

(4) Ps keratanase (although it is an enzyme which degrades keratan sulfate, it is an endo-O-galactosidase type enzyme derived from Pseudomonas sp strain which hydrolyzes a β-galactoside bond of non-sulfated galactose of keratan sulfate; hereinafter, it will be referred to as Ps keratanase; refer, if necessary, to the reference document by Kiyoshi Nakazawa and Sakaru Suzuki, J. Biol. Chem., 250:(3) 912-917 (1975), Purification of Keratan sulfate-endogalactosidase and Its Action on Keratan Sulfate of Different Origin) (0.05 U/200

(5) Physiological saline (200 μL; control)

Experimental Result 1: Evaluation of Motor Neuron Function of Hind Paws (BBB Test)

One day after the injury and once a week from one week after the injury until 10 weeks thereafter, motor neuron function of hind paws was evaluated by using Basso-Beattie-Bresnahan (BBB) scale in accordance with a method of Basso, et al. (Basso, D. M., Beattie, M. S. & Bresnahan, J. C., Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp. Neurol., 139, 244-256 (1996)). The test was conducted under the blind manner by two observers and the quantification was expressed in terms of the value which was an average of the results of two observers. The result is shown in FIG. 1 to FIG. 5.

As will be apparent from FIG. 1, significant recovery of motor neuron function of hind paws was noted in the groups to which Bc keratanase II was administered in an amount of 0.05 U/200 μL and 0.000025 U/200 μl as compared with the group to which physiological saline was administered. Among the above, an effect in the group to which 0.05 U/200 μl was administered was excellent.

As will be apparent from FIG. 2, significant recovery of motor neuron function of hind paws was noted in the groups to which Ks36 keratanase II was administered in an amount of 0.05 U/200 μL and 0.0005 U/200 μl as compared with the group to which physiological saline was administered. Among the above, an effect in the group to which 0.05 U/200 μL was administered was excellent.

As will be apparent from FIG. 3, the effects for the recovery of motor neuron function of hind paws by Bc keratanase II and Ks36 keratanase II were identical when the administered concentration was 0.05 U/200 μL.

As will be apparent from FIG. 4, when the administered concentration was as low as 0.000025 U/200 μL, the effect for the recovery of motor neuron function of hind paws was noted in Bc keratanase II having an excellent heat stability but it was not noted in Ks36 keratanase II. From such results, it has now become clear that, due to its excellent stability, Bc keratanase II exhibits the efficacy in lower dose and is a better treating agent than Ks36 keratanase II.

As will be apparent from FIG. 5, when Bc keratanase II, inactivated Bc keratanase II or Ps keratanase was administered in the administered concentration of 0.05 U/200 μL, the effect for the recovery of motor neuron function of hind paws was noted in Bc keratanase II only. From such results, it has now become clear that a substance which is able to be an active ingredient for a recovery treatment of motor neuron function of hind paws among the enzymes which are called keratanase degrading keratan sulfate is keratanase II and that, since inactivated Bc keratanase II is ineffective, the effect of Bc keratanase II is due to its endo-β-N-acetylglucosaminidase activity.

Experimental Result 2: Evaluation of Motor Neuron Function of Hind Paws (Grid Test)

From one week after the injury until 10 weeks thereafter, rats were placed on a net (grid) of 2 cm×2 cm once a week, let them walk for three minutes and then the times of being able to grip the grid by hind paws and total number of steps were measured. In the total number of steps, the rate where the gripping was possible was used as a % grip value and it was expressed by averaging the values of left and right hind paws. The result where each of Bc keratanase II and Ks36 keratanase II was administered in the administered concentration of 0.05 U/200 μL is shown in FIG. 6, and the result where each of them was administered in the administered concentration of 0.000025 U/200 μL is shown in FIG. 7.

As will be apparent from FIG. 6, the % grip values in the groups to which Bc keratanase II and Ks36 keratanase II were administered were nearly the same when the administered concentration was 0.05 U/200 μL and any of them was higher than the % grip value in the group to which physiological saline was administered.

As will be apparent from FIG. 7, when the administered concentration was as low as 0.000025 U/200 μL, the effect for the recovery of motor neuron function of hind paws was noted in Bc keratanase II having an excellent heat stability but it was not noted in Ks36 keratanase II. From such results, it has now become clear that, due to its excellent stability, Bc keratanase II exhibits the efficacy in lower dose and is a better treating agent than Ks36 keratanase II.

Experimental Result 3: Evaluation of Motor Neuron Function of Hind Paws (Foot Print Test)

One day after the injury and once a week from one week after the injury until 10 weeks thereafter, rat hind paws were covered with an ink to record walking patterns during continuous locomotion on a paper of 50 cm. Each of the right and left step of footprints of the hind paws recorded on the paper was measured and their average value was expressed (unit; mm). The result where each of Bc keratanase II and Ks36 keratanase II was administered in the administered concentration of 0.05 U/200 μL is shown in FIG. 8.

As will be apparent from FIG. 8, the steps in the groups to which Bc keratanase II and Ks36 keratanase II were administered were longer than the step in the group to which physiological saline was administered whereby, in those administered groups, the recovery of motor neuron function of hind paws was noted.

Experimental Result 4: Evaluation of a Therapeutic/Improving Effect for Thermal Allodynia (Action to Thermal Stimulation of Sensory Neuron: Tail Flick Test)

Before the injury and once a week from one week after the injury until 10 weeks thereafter, tails of rats were dipped in a bath of 55° C. and the time until the rats withdrawn their tails (response time) was measured (unit; second(s)). The measurement of the withdrawal latency time was conducted for three times with intervals of 15 minutes and their average value was expressed. The result where each of Bc keratanase II and Ks36 keratanase II was administered in the administered concentration of 0.05 U/200 μL is shown in FIG. 9.

As will be apparent from FIG. 9, in the group to which physiological saline was administered, the response time became short with elapse of time after the injury showing a hypersensitivity reaction to thermal stimulation as compared with before the injury. On the contrary, in the group to which Bc keratanase II and Ks36 keratanase II were administered, although they showed the similar tendency to the case of the group to which physiological saline was administered in an early stage of the injury, the hypersensitivity reaction to thermal stimulation was improved as from the stage of five weeks after the injury and, after eight weeks from the injury, a stable response time almost nearly in the same degree as that before the injury was observed. Thus, in those groups, a significant recovery reaching the normal value of sensory neuron function (therapeutic/improving effect for thermal allodynia) was noted.

Experimental Result 5: Evaluation of a Therapeutic /Improving Effect for Mechanical Allodynia (Action to Pressure Stimulation of Sensory Neuron: Touch Test)

Before the injury and once a week from one week after the injury until 10 weeks thereafter, rats were allowed to stand and habituated for a 15 minutes in a small box. When the rats became calm, von frey filaments (several kinds of filaments where stimulation strengths were different) were applied to the plantar surface of the hind paws from the downside and, with using an up-down method where strong stimulation and weak stimulation were repeated to determine the correct stimulation threshold value (Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., Yaksh, T. L., Quantitative assessment of tactile allodynia in the rat paw., J. Neurosci. Methods, 53, 55-63 (1994)), each of right and left pressure stimulations of the filament by which the rat felt the pain and moved the hind paws was measured and expressed in terms of their average value (unit; gram(s)). The result where each of Bc keratanase II and Ks36 keratanase II was administered in the administered concentration of 0.05 U/200 μL is shown in FIG. 10.

As will be apparent from FIG. 10, in the group to which physiological saline was administered, the pressure stimulation of the filament showed a high value from one week to two weeks after the injury as compared with the stage before the injury showing an insensitivity reaction to the stimulation to the hind paws. However, as from four weeks after the injury, the pressure stimulation of the filament showed low values as compared with the stage before the injury and, after six weeks from the injury, a sensory hypersensitivity symptom where the response was resulted even by a slight stimulation to the hind paws was noted. On the contrary, in the groups to which Bc keratanase II and Ks36 keratanase II were administered, although they showed the similar tendency to the case of the group to which physiological saline was administered until six weeks after the injury, the sensory hypersensitivity reaction was gradually improved as from seven weeks after the injury. After ten weeks from the injury, the pressure stimulation of the filament nearly in the same degree as that before the injury was observed and, in those groups, a significant recovery reaching the normal value of sensory neuron function (therapeutic/improving effect for mechanical allodynia) was noted.

Example 2 Action for Elongating Neurite Lengths and Action for Suppressing Rho Kinase Activation of Keratanase II Experiment 1: Release of Inhibition of Elongation of Neuronal Axon (Experimental Method)

After primary cortical nerve tissue was collected from the brain of mice of one day from birth (P1), the cortex was finely cut, floated in a calcium and magnesium free Hanks buffer (HBSS) and treated with 0.25% of trypsin and 0.1% of deoxyribonuclease (DNase) at 37° C. for 15 minutes. The isolated neurons were made into a cell suspension of 1×10⁵ cells/mL by using Neurobasal medium (Basal Medium for Neuronal Cells; Invitrogen) to which 2% of an additive for the neurons incubation (B27 Supplement for Neuronal Cells) was added. After the cell suspension was seeded onto an 8-well chamber applied with a test sample, it was incubated for one night. Twenty-four hours after starting the incubation of the neurons, the chamber slide was fixed with 4% of paraformaldehyde and the neurons were identified by an immunohistochemical means with Neuronal Class IIIβ tubulin (TUJ1) antibody (COVANCE). The neurite lengths were measured of from 80 to 90 neurons per condition, an average value thereof was calculated and shown by a graph. The test sample was the following three types.

(1) that which was applied with 25 μg/mL of poly-L-lysine (Sigma; hereinafter, the same)

(2) that which was applied with 25 μg/mL of poly-L-lysine followed by being applied with an extracellular proteoglycan mixture solution (PG) (0.5 μg/mL, Chemicon; a mixture of Neurocan, Phosphacan, Versican and Aggrecan; hereinafter, the same)

(3) that which was applied with 25 μg/mL of poly-L-lysine followed by being applied with PG (0.5 μg/mL) and Ks36 keratanase II (0.01 U/mL: Seikagaku Corporation).

(Experimental Result)

The result is shown in FIG. 11. As will be apparent from FIG. 11, an elongation of neurite lengths was inhibited about 70% in the presence of PG containing keratan sulfate, while an inhibiting action for elongation of the neurite lengths induced by PG was released to an extent of nearly 100% in the co-presence of Ks36 keratanase II. From the above result, it has now become clear that keratanase II has a releasing effect for an inhibiting action for the elongation of neurite lengths.

Experiment 2: Suppression of Rho Kinase Activation (Experimental Method)

Next, participation of Rho kinase was investigated in order to investigate the action mechanism of keratanase II in the above Experiment 1. The neurons were seeded onto an 8-well chamber to which a test sample was applied by the same manner as in the method of Experiment 1. Twenty-four hours after starting the incubation of the neurons, 15 μM of Y27632 (Rho kinase inhibitor, Sigma) was added to the neurons followed by incubating for 24 hours more. After that, the chamber was fixed with 4% of paraformaldehyde and the neurons were identified by an immunohistochemical means with Neuronal Class IIIβ tubulin (TUJ1) antibody (COVANCE). The neurite lengths were measured of from 80 to 90 neurons per condition, an average value thereof was calculated and shown by a graph. The test sample was the following four types.

(1) that which was applied with 25 μg/mL of poly-L-lysine (Sigma; hereinafter, the same) followed by being applied with 10 μg/mL of laminin (BD Biosciences; hereinafter, the same).

(2) that which was applied with 25 μg/mL of poly-L-lysine followed by being applied with 10 μg/mL of laminin and 20 μg/mL of keratan sulfate (Seikagaku Corporation; hereinafter, the same).

(3) that which was applied with 25 μg/mL of poly-L-lysine followed by being applied with 10 μg/mL of laminin and 40 μg/mL of keratan sulfate.

(4) that which was applied with 25 μg/mL of poly-L-lysine followed by being applied with 10 μg/mL of laminin, 20 μg/mL of keratan sulfate and Ks36 keratanase II (0.01 U/mL, Seikagaku Corporation).

(Experimental Result)

FIG. 12 shows the pictures under a fluorescent microscope showing the degree of an elongation of the neurite lengths in (a) the case where Y27632 was not added to the test sample (2) and (b) the case where it was added thereto. FIG. 13 shows the results of measurement of the neurite lengths for each test sample where Y27632 was not added and was added. As will be apparent from FIG. 12 and FIG. 13, an inhibiting action for an elongation of neurite lengths induced by keratan sulfate was released by the addition of Y27632. From such results, it was noted that keratan sulfate induces the inhibition of the elongation of the neurite lengths via an Rho kinase activation. It became also clear that, since the inhibiting action for the elongation of the neurite lengths via an Rho kinase activation by keratan sulfate was released by the co-presence of Ks36 keratanase II even if Y27632 was not added, keratanase II suppresses an Rho kinase activation whereby it achieves a releasing effect for an inhibiting action for elongating neurite lengths by keratan sulfate.

Examples 3 Expression of Keratan Sulfate in Spinal Cords of Amyotrophic Lateral Sclerosis (ALS) Model Mice

SOD1-G93A mice which are ALS model mice were purchased from Jackson Laboratory. Spinal cords were excised from two ALS model mice and, after extraction of protein, Western blotting was carried out. Amount of keratan sulfate was detected by anti-keratan sulfate antibody 5D4 (Seikagaku Corporation). As a result, in ALS model mice, increase of the expression of keratan sulfate was detected as compared with the wild type mice (WT) (FIG. 14).

Then, the cells expressing keratan sulfate in spinal cord of ALS model mice were investigated by an immunohistochemical means. Spinal cords of ALS model mice were excised and, after tissue sections were prepared, they were subjected to a double staining with anti-keratan sulfate antibody 5D4 and Iba1 which recognizes a specific marker of microglia cells whereupon expression of keratan sulfate in microglia was confirmed (FIG. 15).

ALS has been known that gliosis occurs therein and, from the above result, it was noted that keratan sulfate is not expressed in astrocyte which is a main body of gliosis but is expressed specifically in microglia which has been said to be closely participated in the onset of disease. Such a phenomenon is able to be said to be an expression mode which is specific to ALS when the fact that, in spinal cord injury and brain stab injury, keratan sulfate is expressed not only in microglia but also in oligodendrocyte is taken into consideration.

Preparation Example 1

rBc keratanase II (genetically recombinant type heat resistant keratanase II) was dissolved in physiological saline to prepare a solution preparation where the concentration was 0.000025 U/mL to 0.05 U/200 μL.

INDUSTRIAL APPLICABILITY

The present invention has an industrial applicability in such a respect that an endo-D-N-acetylglucosaminide type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone is able to be provided as an active ingredient for an improving agent for dysfunction of motor neuron and of sensory neuron due to nerve damage such as spinal cord injury or, to be more specific, for an improving agent for neuropathic pain for example. 

1. An improving agent for dysfunction due to nerve damage, characterized in that, said agent comprising an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient.
 2. The improving agent according to claim 1, wherein the nerve damage is that arising from spinal cord injury.
 3. The improving agent according to claim 1, wherein the nerve damage is amyotrophic lateral sclerosis.
 4. The improving agent according to claim 3, wherein the dysfunction due to nerve damage is motor neuron dysfunction.
 5. The improving agent according to any of claim 3, wherein the dysfunction due to nerve damage is sensory neuron dysfunction.
 6. The improving agent according to claim 5, wherein the sensory neuron dysfunction is neuropathic pain.
 7. The improving agent according to claim 6, wherein the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction.
 8. An improving agent for neuropathic pain, characterized in that, said agent comprising an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in a keratan sulfate backbone as an active ingredient.
 9. An Rho kinase activation inhibitor, characterized in that, said inhibitor comprising an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosaminide bond in the keratan sulfate backbone as an active ingredient.
 10. The improving agent according to claim 1, wherein the dysfunction due to nerve damage is motor neuron dysfunction.
 11. The improving agent according to claim 1, wherein the dysfunction due to nerve damage is sensory neuron dysfunction.
 12. The improving agent according to claim 11, wherein the sensory neuron dysfunction is neuropathic pain.
 13. The improving agent according to claim 12, wherein the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction.
 14. The improving agent according to claim 2, wherein the dysfunction due to nerve damage is motor neuron dysfunction.
 15. The improving agent according to claim 2, wherein the dysfunction due to nerve damage is sensory neuron dysfunction.
 16. The improving agent according to claim 15, wherein the sensory neuron dysfunction is neuropathic pain.
 17. The improving agent according to claim 16, wherein the neuropathic pain is a pain caused by allodynia or hyperalgesic reaction. 